Company profile: Annexon Biosciences
1.1 - Company Overview
Company description
- Provider of complement-targeting therapeutics focused on C1q, including ANX005 to inhibit the classical complement pathway for autoimmune and neurodegenerative disorders; ANX007, an intravitreal therapy for glaucoma and other ophthalmic conditions; ANX009, a subcutaneous therapy for systemic autoimmune diseases; and ANX1502, an early-stage candidate for complement-mediated diseases.
Products and services
- ANX007: C1q-targeted intravitreal therapy for glaucoma and other ophthalmic conditions, locally inhibiting the classical complement pathway within the eye to protect retinal tissues and preserve vision
- ANX009: C1q-targeted subcutaneous therapy for systemic autoimmune diseases, delivering body-wide inhibition of the classical complement pathway to reduce complement-driven inflammation and prevent tissue injury
- ANX005: C1q-targeted therapeutic antibody that inhibits the classical complement pathway to treat autoimmune and neurodegenerative disorders by binding C1q and preventing pathway activation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Annexon Biosciences
Afferent Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for chronic pain, developing medicines that target P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afferent Pharmaceuticals company profile →
Oculogica
HQ: United States
Website
- Description: Provider of neuro-diagnostic medical devices and training focused on TBI, concussion, and eye-tracking. Products include EyeBOX, an FDA-cleared, baseline-free, non-invasive device that tracks eye movements to aid in concussion (mTBI) diagnosis with results in under four minutes, and OcuPro, a roadside test for law enforcement to detect recent cannabis use and impairment. Offers EyeBOX training to customers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oculogica company profile →
Kineta
HQ: United States
Website
- Description: Provider of biotechnology drug discovery focused on diseases caused by protein misfolding, offering immunotherapies such as KVA12123, a VISTA-blocking agent in Phase 1/2 trials as monotherapy and with pembrolizumab, and an anti-CD27 agonist mAb to activate T and NK cells and address exhausted T cells in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kineta company profile →
Premier Biotech
HQ: United States
Website
- Description: Provider of drug testing diagnostic devices and laboratory services, including drugs of abuse testing delivering accurate results in under 10 minutes with observed collection to prevent adulteration. Offers the OT-Scan app for capturing and reporting drug screen results with automated test interpretation, secure data transmission, and in-app confirmation testing ordering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Premier Biotech company profile →
Salvia BioElectronics
HQ: The Netherlands
Website
- Description: Provider of neuromodulation devices for migraine, including a paper-thin implant placed under the skin near nerves associated with migraine to deliver gentle electrical pulses, the MySalvia external device to activate therapy, and the MySalvia app for monitoring and personalized treatment; also exploring bioelectronic therapy for cluster headache.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salvia BioElectronics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Annexon Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Annexon Biosciences
2.2 - Growth funds investing in similar companies to Annexon Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Annexon Biosciences
4.2 - Public trading comparable groups for Annexon Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →